Flatiron Bio creates therapeutics and medical devices targeting autoimmunity, cancer, and broader healthcare challenges. By partnering with entrepreneurs and funding programs, the company accelerates the development of next‑generation medicines and innovative medical technologies. Their portfolio includes both drug candidates and device solutions designed to address unmet clinical needs in the San Francisco Bay Area and beyond.
Funding
Funding not disclosed
Founders
Product
Problem
Developing new therapeutics and medical devices for autoimmunity, cancer, and other health conditions often requires both deep scientific expertise and substantial capital, creating bottlenecks that delay patient access to innovative treatments.
Solution
Flatiron Bio addresses this gap by simultaneously operating as a product development organization and a strategic investor. The company advances its own pipeline of therapeutics and medical devices while providing capital, mentorship, and operational support to external entrepreneurs and programs developing next‑generation medicines. By integrating scientific development with funding and execution resources, Flatiron Bio shortens the timeline from discovery to clinical testing and ultimately to market availability.
Target Audience
Primary customers are biotech startups, academic spin‑outs, and established pharmaceutical companies seeking development expertise and funding for autoimmune, cancer, and broader healthcare projects.
Features
- In‑house development of novel therapeutics targeting autoimmune diseases and oncology
- Design and engineering of medical devices that complement therapeutic strategies
- Strategic investment platform that supplies seed and growth capital to early‑stage biotech ventures
- Hands‑on operational support including regulatory guidance, pre‑clinical testing, and manufacturing scale‑up
- Collaborative partnership model that aligns incentives between Flatiron Bio and external innovators